Literature DB >> 11714962

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine.

Gregory A Prince1, Spencer J Curtis1, Kevin C Yim1, David D Porter2.   

Abstract

A formalin-inactivated respiratory syncytial virus vaccine was used to immunize infants in the mid-1960s; when these children later were naturally infected by the virus they developed markedly accentuated disease, and two died. For the present work, a new batch of vaccine was prepared using the original formula. Administration of either the old or new vaccines resulted in enhanced lesions in immunized cotton rats subsequently challenged with live virus, although administration of the vaccine reduced virus replication by 90%. Animals primed with formalin-inactivated virus and challenged developed markedly accentuated lesions of the same type as in animals undergoing primary or secondary infection. In addition, the animals with the vaccine-enhanced disease developed alveolitis and interstitial pneumonitis, which appear to be specific markers for the vaccine enhancement. The newly prepared vaccine appears suitable as a reference standard for studying the mechanism of vaccine-enhanced disease caused by this virus. Additionally, we reviewed the lesions in the lungs of the two humans who died with the vaccine-enhanced disease in 1967, and found that they were similar to, but more severe than those seen in the cotton rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714962     DOI: 10.1099/0022-1317-82-12-2881

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  105 in total

1.  Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Authors:  Ruihong Zeng; Huixian Zhang; Yan Hai; Yuxiu Cui; Lin Wei; Na Li; Jianxun Liu; Caixia Li; Ying Liu
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.

Authors:  Kirsten Schneider-Ohrum; Corinne Cayatte; Angie Snell Bennett; Gaurav Manohar Rajani; Patrick McTamney; Krystal Nacel; Leigh Hostetler; Lily Cheng; Kuishu Ren; Terrence O'Day; Gregory A Prince; Michael P McCarthy
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.

Authors:  Christina A Rostad; Christopher C Stobart; Brian E Gilbert; Ray J Pickles; Anne L Hotard; Jia Meng; Jorge C G Blanco; Syed M Moin; Barney S Graham; Pedro A Piedra; Martin L Moore
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

5.  Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice.

Authors:  Leslie van der Fits; Renske Bolder; Marjolein Heemskerk-van der Meer; Joke Drijver; Yolinda van Polanen; Jan Serroyen; Johannes P M Langedijk; Hanneke Schuitemaker; Eirikur Saeland; Roland Zahn
Journal:  NPJ Vaccines       Date:  2020-06-12       Impact factor: 7.344

6.  Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors:  Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

Review 7.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

8.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Authors:  Young-Man Kwon; Hye Suk Hwang; Jong Seok Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Jae-Min Song; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

10.  Inactivation of respiratory syncytial virus by zinc finger reactive compounds.

Authors:  Marina S Boukhvalova; Gregory A Prince; Jorge C G Blanco
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.